

Marcel B Bally

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/3350591/publications.pdf](https://exaly.com/author-pdf/3350591/publications.pdf)

Version: 2025-02-01

175
papers

10,348
citations

21829

55
h-index

32271

94
g-index

180
all docs

180
docs citations

180
times ranked

11986
citing authors

#	ARTICLE	IF	CITATIONS
1	Monolignol export by diffusion down a polymerization-induced concentration gradient. <i>Plant Cell</i> , 2022, 34, 2080-2095.	7.6	45
2	DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation. <i>Journal of Controlled Release</i> , 2022, 345, 75-90.	11.3	8
3	Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia. <i>Journal of Controlled Release</i> , 2021, 333, 246-257.	11.3	21
4	Liposomal OTS964, a TOPK inhibitor: a simple method to estimate OTS964 association with liposomes that relies on enhanced OTS964 fluorescence when bound to albumin. <i>Drug Delivery and Translational Research</i> , 2019, 9, 1082-1094.	4.7	4
5	Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia. <i>Pharmaceutical Research</i> , 2019, 36, .	3.9	48
6	What Drives Innovation: The Canadian Touch on Liposomal Therapeutics. <i>Pharmaceutics</i> , 2019, 11, 124.	5.2	22
7	Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use. <i>Drug Delivery and Translational Research</i> , 2019, 10, 202-215.	4.7	24
8	Transition Metal Ions Promote the Bioavailability of Hydrophobic Therapeutics: Cu and Zn Interactions with RNA Polymerase II Inhibitor CX5461. <i>Chemistry - A European Journal</i> , 2018, 24, 6334-6338.	3.5	6
9	Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2922.	4.5	37
10	Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor. <i>Journal of Controlled Release</i> , 2018, 286, 1-9.	11.3	15
11	Developing liposomal nanomedicines for treatment of patients with neuroblastoma. , 2018, , 361-411.		4
12	CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours. <i>Nature Communications</i> , 2017, 8, .	14.1	382
13	In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization. <i>Drug Delivery and Translational Research</i> , 2017, 7, 544-557.	4.7	7
14	Optimization of liposomal topotecan for use in treating neuroblastoma. <i>Cancer Medicine</i> , 2017, 6, 1240-1254.	2.8	18
15	A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer. <i>Journal of Controlled Release</i> , 2017, 252, 50-61.	11.3	35
16	Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status. <i>Investigational New Drugs</i> , 2017, 35, 682-690.	2.6	30
17	<i>In Vivo</i> Validation of PAPSS1 (3- β -phosphoadenosine 5-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target. <i>Clinical Cancer Research</i> , 2017, 23, 6555-6566.	6.4	10
18	A Perspective "Can copper complexes be developed as a novel class of therapeutics?". <i>Dalton Transactions</i> , 2017, 46, 10758-10773.	3.2	149

#	ARTICLE	IF	CITATIONS
19	Unique therapeutic properties and preparation methodology of multivalent rituximab-lipid nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 117, 256-269.	4.2	4
20	Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 4129-4146.	5.4	55
21	Development of a copper-cloiquinol formulation suitable for intravenous use. <i>Drug Delivery and Translational Research</i> , 2017, 8, 239-251.	4.7	28
22	Sulfonation, an underexploited area: from skeletal development to infectious diseases and cancer. <i>Oncotarget</i> , 2016, 7, 55811-55827.	1.7	38
23	Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development. <i>PLoS ONE</i> , 2016, 11, e0153416.	2.5	41
24	Overexpression of HER-2 in MDA-MB-435/LCC6 Tumours is Associated with Higher Metabolic Activity and Lower Energy Stress. <i>Scientific Reports</i> , 2016, 6, .	3.7	1
25	PRCosomes: pretty reactive complexes formed in liposomes. <i>Journal of Drug Targeting</i> , 2016, 24, 787-796.	4.0	19
26	Synthetic lethality in lung cancer and translation to clinical therapies. <i>Molecular Cancer</i> , 2016, 15, .	29.8	27
27	Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinoma. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2016, 1858, 3195-3204.	2.2	63
28	Abstract 1319: A novel formulation of CX-5461, a small-molecule inhibitor of rRNA synthesis, and its use for treatment of acute myeloid leukemia models. <i>Cancer Research</i> , 2016, 76, 1319-1319.	0.6	4
29	Abstract 2206: Development and characterization of an injectable copper cloiquinol formulation: repurposing of a topical antifungal for treatment of cancer. , 2016, , .		1
30	Abstract 3914: Repurposing disulfiram for use as an anticancer drug: a story about metabolism and metal binding. , 2016, , .		1
31	Combined Use of Gene Expression Modeling and siRNA Screening Identifies Genes and Pathways Which Enhance the Activity of Cisplatin When Added at No Effect Levels to Non-Small Cell Lung Cancer Cells In Vitro. <i>PLoS ONE</i> , 2016, 11, e0150675.	2.5	12
32	Identification of breast cancer cell subtypes sensitive to ATG4B inhibition. <i>Oncotarget</i> , 2016, 7, 66970-66988.	1.7	52
33	Using Pharmacokinetic Profiles and Digital Quantification of Stained Tissue Microarrays as a Medium-Throughput, Quantitative Method for Measuring the Kinetics of Early Signaling Changes Following Integrin-Linked Kinase Inhibition in an In Vivo Model of Cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2015, 63, 691-709.	1.5	6
34	Irinophore C ₆₀ , a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer. <i>Journal of Controlled Release</i> , 2015, 199, 72-83.	11.3	21
35	3 ^{â€²} -Phosphoadenosine 5 ^{â€²} -phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents. <i>Oncotarget</i> , 2015, 6, 17161-17177.	1.7	16
36	Irinophore C ₆₀ , a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities. <i>Investigational New Drugs</i> , 2014, 32, 1071-1082.	2.6	14

#	ARTICLE	IF	CITATIONS
37	Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3159-3173.	6.4	125
38	Harnessing The Potential of Lipid-Based Nanomedicines for Type-Specific Ovarian Cancer Treatments. <i>Nanomedicine</i> , 2014, 9, 501-522.	3.1	10
39	Topotecan and Doxorubicin Combination to Treat Recurrent Ovarian Cancer: The Influence of Drug Exposure Time and Delivery Systems to Achieve Optimum Therapeutic Activity. <i>Clinical Cancer Research</i> , 2013, 19, 865-877.	6.4	25
40	Characterization of Long-Circulating Cationic Nanoparticle Formulations Consisting of a Two-Stage PEGylation Step for the Delivery of siRNA in a Breast Cancer Tumor Model. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 227-236.	3.4	26
41	Nano-Encapsulation of Arsenic Trioxide Enhances Efficacy against Murine Lymphoma Model while Minimizing Its Impact on Ovarian Reserve In Vitro and In Vivo. <i>PLoS ONE</i> , 2013, 8, e58491.	2.5	59
42	Liposomes. , 2013, , 27-63.		11
43	Combined RNAi-Mediated Suppression of Rictor and EGFR Resulted in Complete Tumor Regression in an Orthotopic Glioblastoma Tumor Model. <i>PLoS ONE</i> , 2013, 8, e59597.	2.5	23
44	Treatment of Colorectal Cancer Using a Combination of Liposomal Irinotecan (Irinophore Câ,,ç) and 5-Fluorouracil. <i>PLoS ONE</i> , 2013, 8, e62349.	2.5	26
45	Induction of Autophagy Is an Early Response to Gefitinib and a Potential Therapeutic Target in Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e76503.	2.5	83
46	A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form. <i>Drug Safety</i> , 2012, 24, 903-920.	3.2	144
47	A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer. <i>Anti-Cancer Drugs</i> , 2012, 23, 543-552.	1.5	33
48	Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer. <i>Investigational New Drugs</i> , 2012, 31, 46-58.	2.6	25
49	Multivalent Rituximab Lipid Nanoparticles as Improved Lymphoma Therapies: Indirect Mechanisms of Action and <i>In Vivo</i> Activity. <i>Nanomedicine</i> . 2011. 6. 1575-1591.	3.1	16
50	Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors. <i>Cancer Research</i> , 2011, 71, 3364-3376.	0.6	633
51	Development of a liposomal nanoparticle formulation of 5-Fluorouracil for parenteral administration: Formulation design, pharmacokinetics and efficacy. <i>Journal of Controlled Release</i> , 2011, 150, 212-219.	11.3	62
52	Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore Câ,,ç), doxorubicin (Caelyx®) or vincristine. <i>BMC Cancer</i> , 2011, 11, .	3.0	47
53	The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity. <i>BMC Cancer</i> , 2011, 11, .	3.0	23
54	Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267. <i>Cancer Biology and Therapy</i> , 2011, 11, 826-838.	4.3	21

#	ARTICLE	IF	CITATIONS
55	A Low Carbohydrate, High Protein Diet Slows Tumor Growth and Prevents Cancer Initiation. <i>Cancer Research</i> , 2011, 71, 4484-4493.	0.6	102
56	Lipid-Based Nanoformulation of Irinotecan: Dual Mechanism of Action Allows for Combination Chemo/Angiogenic Therapy. <i>Nanomedicine</i> , 2011, 6, 1645-1654.	3.1	4
57	Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. <i>Journal of Controlled Release</i> , 2010, 144, 332-340.	11.3	77
58	The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 2295-2308.	3.4	100
59	Characterization of Cationic Liposome Formulations Designed to Exhibit Extended Plasma Residence Times and Tumor Vasculature Targeting Properties. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 2839-2853.	3.4	33
60	Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer. <i>Prostate</i> , 2010, 70, 1437-1447.	2.2	29
61	The Role of the Transition Metal Copper and the Ionophore A23187 in the Development of Irinophore C ₁ . <i>Pharmaceutical Research</i> , 2010, 28, 848-857.	3.9	9
62	siRNA-Mediated Integrin-Linked Kinase Suppression: Nonspecific Effects of siRNA/Cationic Liposome Complexes Trigger Changes in the Expression of Phosphorylated-AKT and mTOR Independently of ILK Silencing. <i>Oligonucleotides</i> , 2009, 19, 129-140.	3.8	8
63	Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1085-1095.	2.3	44
64	QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. <i>Breast Cancer Research</i> , 2009, 11, .	5.0	57
65	Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging. <i>Journal of Physical Chemistry C</i> , 2009, 113, 20252-20258.	3.2	22
66	Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. <i>International Journal of Pharmaceutics</i> , 2008, 349, 38-46.	4.9	54
67	A novel liposomal irinotecan formulation with significant anti-tumour activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 68, 607-617.	4.2	42
68	Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor- κ B, p53, bax, and p27 levels. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 749-758.	1.7	37
69	Rictor and Integrin-Linked Kinase Interact and Regulate Akt Phosphorylation and Cancer Cell Survival. <i>Cancer Research</i> , 2008, 68, 1618-1624.	0.6	180
70	Irinophore C, a Novel Nanoformulation of Irinotecan, Alters Tumor Vascular Function and Enhances the Distribution of 5-Fluorouracil and Doxorubicin. <i>Clinical Cancer Research</i> , 2008, 14, 7260-7271.	6.4	44
71	Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 1208-1217.	6.4	35
72	Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of Integrin-linked kinase (ILK). <i>Molecular Cancer Therapeutics</i> , 2008, 7, 59-70.	1.7	53

#	ARTICLE	IF	CITATIONS
73	A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity. <i>Letters in Drug Design and Discovery</i> , 2007, 4, 426-433.	1.3	5
74	Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 844-855.	1.7	46
75	In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2007, 65, 289-299.	4.2	28
76	Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2007, 1768, 678-687.	2.2	109
77	Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2007, 1768, 1367-1377.	2.2	281
78	Magnetic Resonance Imaging of Temperature-Sensitive Liposome Release: Drug Dose Painting and Antitumor Effects. <i>Journal of the National Cancer Institute</i> , 2007, 99, 53-63.	5.1	243
79	Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 319-331.	2.5	16
80	Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1854-1863.	1.7	285
81	Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. <i>Leukemia Research</i> , 2006, 30, 449-457.	0.6	29
82	A Parenteral Econazole Formulation Using a Novel Micelle-to-Liposome Transfer Method: In Vitro Characterization and Tumor Growth Delay in a Breast Cancer Xenograft Model. <i>Pharmaceutical Research</i> , 2006, 23, 2575-2585.	3.9	106
83	Transition Metal-Mediated Liposomal Encapsulation of Irinotecan (CPT-11) Stabilizes the Drug in the Therapeutically Active Lactone Conformation. <i>Pharmaceutical Research</i> , 2006, 23, 2799-2808.	3.9	39
84	Copper ²⁺ -topotecan complexation mediates drug accumulation into liposomes. <i>Journal of Controlled Release</i> , 2006, 114, 78-88.	11.3	62
85	Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. <i>Magnetic Resonance in Medicine</i> , 2006, 56, 1011-1018.	3.1	112
86	Temporal targeting in cancer: combined chemotherapy and antiangiogenic therapy. <i>Nanomedicine</i> , 2006, 1, 359-363.	3.1	0
87	Gene Silencing in the Development of Personalized Cancer Treatment: The Targets, the Agents and the Delivery Systems. <i>Current Gene Therapy</i> , 2006, 6, 505-533.	3.0	16
88	Preferential Dependence of Breast Cancer Cells versus Normal Cells on Integrin-Linked Kinase for Protein Kinase B/Akt Activation and Cell Survival. <i>Cancer Research</i> , 2006, 66, 393-403.	0.6	104
89	Irinotecan ²⁺ -cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 60, 91-102.	2.3	12
90	A Parenteral Econazole Formulation Using a Novel Micelle-to-Liposome Transfer Method: In Vitro Characterization and Tumor Growth Delay in a Breast Cancer Xenograft Model. <i>Pharmaceutical Research</i> , 2006, 23, 2575-2585.	3.9	8

#	ARTICLE	IF	CITATIONS
91	Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. <i>Oncogene</i> , 2005, 24, 3596-3605.	6.6	95
92	Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. <i>Journal of Controlled Release</i> , 2005, 104, 271-288.	11.3	104
93	Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. <i>Journal of Controlled Release</i> , 2005, 105, 89-105.	11.3	35
94	The Formulation of Lipid-Based Nanotechnologies for the Delivery of Fixed Dose Anticancer Drug Combinations. <i>Current Drug Delivery</i> , 2005, 2, 341-351.	2.6	43
95	Preparation, Characterization, and Biological Analysis of Liposomal Formulations of Vincristine. <i>Methods in Enzymology</i> , 2005, , 40-57.	1.0	46
96	The Liposomal Formulation of Doxorubicin. <i>Methods in Enzymology</i> , 2005, , 71-97.	1.0	333
97	Antitumor Efficacy of Oblimersen Bcl-2 Antisense Oligonucleotide Alone and in Combination with Vinorelbine in Xenograft Models of Human Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 7662-7670.	6.4	29
98	Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction. <i>Clinical Cancer Research</i> , 2004, 10, 2512-2524.	6.4	74
99	Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model. <i>Cancer Biology and Therapy</i> , 2004, 3, 197-204.	4.3	25
100	In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading. <i>Clinical Cancer Research</i> , 2004, 10, 728-738.	6.4	85
101	Liposomal Irinotecan. <i>Clinical Cancer Research</i> , 2004, 10, 6638-6649.	6.4	70
102	An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. <i>Journal of Controlled Release</i> , 2004, 96, 449-461.	11.3	85
103	In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery. <i>Magnetic Resonance in Medicine</i> , 2004, 51, 1153-1162.	3.1	164
104	pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2004, 1661, 47-60.	2.2	83
105	Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. <i>Vaccine</i> , 2004, 22, 1985-1991.	3.2	44
106	HER-2/neu Overexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization. <i>Molecular Cancer Research</i> , 2004, 2, 606-619.	2.9	24
107	Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model. <i>Journal of Experimental Therapeutics and Oncology</i> , 2003, 3, 261-271.	1.7	4
108	Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2003, 1613, 115-121.	2.2	32

#	ARTICLE	IF	CITATIONS
109	Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. <i>Vaccine</i> , 2003, 21, 3319-3329.	3.2	57
110	Prevention of Antibody-Mediated Elimination of Ligand-Targeted Liposomes by Using Poly(Ethylene) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	3.5	35
111	Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2002, 1560, 37-50.	2.2	28
112	Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2002, 1561, 188-201.	2.2	57
113	Formation of transition metalâ€doxorubicin complexes inside liposomes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2002, 1565, 41-54.	2.2	144
114	Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2002, 1567, 204-212.	2.2	52
115	Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. <i>International Journal of Pharmaceutics</i> , 2002, 241, 57-64.	4.9	11
116	Oxazole yellow homodimer YOYO-1-labeled DNA: a fluorescent complex that can be used to assess structural changes in DNA following formation and cellular delivery of cationic lipid DNA complexes. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2001, 1527, 61-72.	2.0	20
117	Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2001, 1510, 56-69.	2.2	52
118	Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2001, 1513, 25-37.	2.2	106
119	Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2001, 1513, 193-206.	2.2	34
120	Title is missing!. <i>Pharmaceutical Research</i> , 2001, 18, 1331-1335.	3.9	7
121	Characterization of hybrid CTL epitope delivery systems consisting of the Antennapedia homeodomain peptide vector formulated in liposomes. <i>Journal of Immunological Methods</i> , 2001, 254, 119-135.	1.5	16
122	Efficient Delivery of Antennapedia Homeodomain Fused to CTL Epitope with Liposomes into Dendritic Cells Results in the Activation of CD8+ T Cells. <i>Journal of Immunology</i> , 2001, 167, 6462-6470.	0.6	51
123	Use of Poly(ethylene glycol)â€Lipid Conjugates to Regulate the Surface Attributes and Transfection Activity of Lipidâ€DNA Particles. , 2000, 89, 652-663.		140
124	Designing Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications. <i>Journal of Liposome Research</i> , 2000, 10, 99-115.	3.8	26
125	Antibody Conjugation Methods for Active Targeting of Liposomes. , 2000, , 51-68.		19
126	Targeted Gene Transfer: A Practical Guide Based on Experience with Lipid-Based Plasmid Delivery Systems. , 2000, , 255-304.		0

#	ARTICLE	IF	CITATIONS
127	Clinical and Preclinical Pharmacology of Liposomal Vincristine. <i>Journal of Liposome Research</i> , 2000, 10, 501-512.	3.8	4
128	Liposomal Anticancer Drugs as Agents to be used in Combination with other Anticancer Agents: Studies on a Liposomal Formulation with two Encapsulated Drugs. <i>Journal of Liposome Research</i> , 1999, 9, 507-522.	3.8	9
129	Intravenous Pretreatment with Empty pH Gradient Liposomes Alters the Pharmacokinetics and Toxicity of Doxorubicin through In Vivo Active Drug Encapsulation. <i>Journal of Pharmaceutical Sciences</i> , 1999, 88, 96-102.	3.4	31
130	Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. <i>Nature Biotechnology</i> , 1999, 17, 775-779.	18.1	112
131	Biological barriers to cellular delivery of lipid-based DNA carriers. <i>Advanced Drug Delivery Reviews</i> , 1999, 38, 291-315.	15.7	157
132	A multi-step lipid mixing assay to model structural changes in cationic lipoplexes used for in vitro transfection. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1999, 1461, 27-46.	2.2	39
133	Electrostatically Mediated Interactions between Cationic Lipid-DNA Particles and an Anionic Surface. <i>Archives of Biochemistry and Biophysics</i> , 1999, 366, 31-39.	2.7	7
134	Cationic Liposome-Plasmid DNA Complexes Used for Gene Transfer Retain a Significant Trapped Volume. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 9-14.	3.4	11
135	Clearance properties of liposomes involving conjugated proteins for targeting. <i>Advanced Drug Delivery Reviews</i> , 1998, 32, 99-118.	15.7	44
136	Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 41, 347-352.	2.3	33
137	Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 461-470.	2.3	56
138	Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1998, 1372, 272-282.	2.2	140
139	Characterization of Lipid DNA Interactions. I. Destabilization of Bound Lipids and DNA Dissociation. <i>Biophysical Journal</i> , 1998, 75, 1040-1051.	0.4	79
140	Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations. <i>Journal of Liposome Research</i> , 1998, 8, 299-335.	3.8	33
141	Liposomal Vincristine: The Central Role of Drug Retention in Defining Therapeutically Optimized Anticancer Formulations. , 1998, , 29-49.		9
142	Human gene therapy: principles and modern advances. <i>Biotechnology Annual Review</i> , 1997, , 59-110.	0.0	1
143	Analysis of Cationic Liposome-mediated Interactions of Plasmid DNA with Murine and Human Melanoma Cells in Vitro. <i>Journal of Biological Chemistry</i> , 1997, 272, 19480-19487.	2.3	28
144	Liposome Targeting Following Intravenous Administration: Defining Expectations and a Need for Improved Methodology. <i>Journal of Liposome Research</i> , 1997, 7, 331-361.	3.8	9

#	ARTICLE	IF	CITATIONS
145	Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. <i>BBA - Biomembranes</i> , 1997, 1331, 187-211.	11.0	171
146	An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin. <i>Journal of Immunological Methods</i> , 1997, 210, 137-148.	1.5	22
147	Lipid/DNA complexes as an intermediate in the preparation of particles for gene transfer: an alternative to cationic liposome/DNA aggregates. <i>Advanced Drug Delivery Reviews</i> , 1997, 24, 275-290.	15.7	29
148	Title is missing!. <i>Pharmaceutical Research</i> , 1997, 14, 190-196.	3.9	53
149	Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 309-317.	2.3	47
150	Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1997, 16, 675-687.	3.2	34
151	Genetic allogeneization of malignant melanoma. <i>Transfusion Science</i> , 1996, 17, 169-174.	0.8	5
152	Cationic Lipid Binding to DNA: Characterization of Complex Formation. <i>Biochemistry</i> , 1996, 35, 5756-5763.	2.9	103
153	Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 37, 351-355.	2.3	33
154	Plasmid DNA is Protected against Ultrasonic Cavitation-Induced Damage when Complexed to Cationic Liposomes. <i>Journal of Pharmaceutical Sciences</i> , 1996, 85, 427-433.	3.4	62
155	LIPOSOMAL CYCLOSPORINE. <i>Transplantation</i> , 1995, 60, 1006.	1.0	16
156	A model approach for assessing liposome targeting in vivo. <i>Drug Delivery</i> , 1995, 2, 156-165.	7.9	2
157	Encapsulation of Vincristine in Liposomes Reduces its Toxicity and Improves its Anti-Tumor Efficacy. <i>Journal of Liposome Research</i> , 1995, 5, 523-541.	3.8	49
158	Poly(ethylene glycol)-Modified Phospholipids Prevent Aggregation during Covalent Conjugation of Proteins to Liposomes. <i>Bioconjugate Chemistry</i> , 1995, 6, 187-194.	3.9	55
159	The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: Implications for drug delivery. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1995, 1238, 147-155.	2.2	41
160	Formation of Novel Hydrophobic Complexes between Cationic Lipids and Plasmid DNA. <i>Biochemistry</i> , 1995, 34, 12877-12883.	2.9	114
161	A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 91-101.	2.3	29
162	The Use of Transmembrane pH Gradient-Driven Drug Encapsulation in the Pharmacodynamic Evaluation of Liposomal Doxorubicin. <i>Journal of Liposome Research</i> , 1994, 4, 529-553.	3.8	35

#	ARTICLE	IF	CITATIONS
163	Polyethylene Glycol Modified Phospholipids Stabilize Emulsions Prepared from Triacylglycerol. <i>Journal of Pharmaceutical Sciences</i> , 1994, 83, 1558-1564.	3.4	57
164	Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 137-146.	2.3	48
165	Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. <i>Anti-Cancer Drugs</i> , 1994, 5, 579-590.	1.5	41
166	The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. <i>Lipids and Lipid Metabolism</i> , 1993, 1168, 249-252.	2.7	23
167	Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 33, 17-24.	2.3	71
168	Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 27, 13-19.	2.3	62
169	The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. <i>Chemistry and Physics of Lipids</i> , 1990, 53, 37-46.	2.7	210
170	Liposomes with entrapped doxorubicin exhibit extended blood residence times. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1990, 1023, 133-139.	2.2	95
171	Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1990, 1025, 143-151.	2.2	208
172	Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. <i>Chemistry and Physics of Lipids</i> , 1988, 47, 97-107.	2.7	40
173	A non-covalent method of attaching antibodies to liposomes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1987, 901, 157-160.	2.2	60
174	Techniques for encapsulating bioactive agents into liposomes. <i>Chemistry and Physics of Lipids</i> , 1986, 40, 333-345.	2.7	149
175	Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1985, 816, 294-302.	2.2	138